Trial
NCT02179151
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Zafgen, Inc.
Collaborators
—
Condition
Prader-Willi Syndrome
Intervention
ZGN-440 for Injectable Suspension
Why stopped
FDA Clinical Hold
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-26